Dyne Therapeutics initiated with an Outperform at RBC Capital
RBC Capital analyst Luca Issi initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $45 price target. Dyne’s lead program ...
Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated at Royal Bank of Canada
Analysts at Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report ...
Dyne Therapeutics Receives Buy Rating Following IND Clearance and Promising Trial Updates
Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of “Buy” from Analysts
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) has been given a consensus rating of “Buy” by the ten ratings firms ...